A rterial flow-mediated dilation (FMD) is an indirect measurement of endothelial nitric oxide (NO) release. 1 Impaired FMD represents systemic vascular endothelial dysfunction that is commonly associated with cardiovascular disease (CVD). 2, 3 In addition, the association of FMD with CVD is evidenced by its ability to predict future CVD events in population-based studies. 4, 5 Endothelial dysfunction, defined by impaired FMD, has been reported in patients with atrial fibrillation (AF). 6,7 Also, abnormalities in NO signaling have been implicated in atrial ectopy near the pulmonary veins. 8, 9 These findings suggest a potential role for endothelial dysfunction in the development of AF. However, data from population-based studies to support this claim are lacking. The purpose of this study was to examine the association of brachial FMD with incident AF in the Multi-Ethnic Study of Atherosclerosis (MESA).
participants missing either baseline characteristics or medication data were excluded. A total of 2936 study participants (mean age, 61±9.9 years; 50% women; 66% nonwhites) were included in the final analysis.
FMD was computed from the percentage difference (%FMD) in brachial artery diameter and maximum diameter during measured vasodilator responses. Baseline characteristics stratified by sex-specific median %FMD are shown in Table 1 . Participants with %FMD values below the median were more likely to be older, diabetic, and nonwhite and to have lower educational attainment and income compared with higher %FMD values. Persons with %FMD values below the median value were more likely to have increased values for systolic blood pressure and high-density lipoprotein cholesterol, and lower values for total cholesterol than those with %FMD values above the median value. Higher rates of antihypertensive medications, aspirin, lipid-lowering therapies, and left ventricular hypertrophy also were observed in people with %FMD values below the median value.
A total of 137 (4.7%) participants developed AF during the study period. Median follow-up for study participants was 8.5 years (interquartile range, 7.9-8.7). Unadjusted cumulative incidence curves stratified by median %FMD are shown in the Figure. Participants with %FMD less than the median value (incidence rate per 1000 person-years, 7.3; 95% confidence interval, 5.9-9.0) were more likely to develop AF compared with participants who had %FMD values greater than the median value (incidence rate per 1000 person-years, 4.5; 95% confidence interval, 3.4-5.8; log-rank P=0.0043).
In a multivariable Cox proportional-hazards analysis, each 1-SD increase in %FMD values (SD, 2.8%) was associated with less incident AF ( Table 2 ). The association between FMD and AF remained significant after further adjustment of model 2 with amino-terminal pro-brain natriuretic peptide (hazard ratio, 0.83; 95% confidence interval, 0.69-0.99). These results were consistent across subgroups of MESA participants stratified by age, sex, and race/ethnicity ( Table 2 ).
Discussion
In this analysis from MESA, lower brachial FMD values were associated with increased rates of AF. These findings suggest that endothelial dysfunction, as measured by brachial FMD, plays a role in the pathogenesis of AF.
To our knowledge, only 2 studies have examined the association of brachial FMD with AF. A study of chronic AF participants showed that FMD measurements are significantly impaired compared with sinus rhythm controls. 6 Another case-control study showed that participants with persistent AF have impaired FMD and that FMD improves after the restoration of sinus rhythm. 7 However, both studies examined FMD among participants who already had AF. The current study examined FMD among participants without diagnosed AF and showed that lower FMD values are associated with an increased risk of AF development. In addition, participants with lower %FMD values were observed to have a higher incidence of AF than those in the general population. 10 Therefore, our results provide evidence that impaired FMD precedes the development of AF, suggesting a role for endothelial dysfunction in AF pathogenesis.
Endothelial cells regulate oxidative stress, vascular permeability, platelet aggregation, thrombosis, and vascular tone by controlling the release of several vasoactive substances, including NO. 11 The dysfunctional endothelium results in the downregulation of NO and the upregulation of adhesion †Statistical significance was tested for categorical variables using the χ 2 method and for continuous variables the Wilcoxon rank-sum method was used.
molecules that promote increased levels of inflammation and oxidative stress. Recent evidence suggests that increased oxidant generation by endothelial NADPH oxidase promotes the uncoupling of NO synthase and subsequent generation of reactive oxygen species and oxidative injury that leads to the electrophysiological remodeling observed in AF. 8 In addition, exogenous NO has been shown to reduce spontaneous electric activity in cardiomyocytes isolated from the pulmonary vein, implicating NO as a regulator of AF arrhythmiogenesis. 9 Endothelial dysfunction also is associated with increased levels of inflammation that result in atrial ectopy in discharging cells near the pulmonary veins. 12, 13 It is plausible that persons with endothelial dysfunction are more likely to have dysfunctional regulation of the aforementioned processes that increase their risk for AF. Therefore, FMD potentially is able to identify abnormal vascular biological profiles that precede AF development.
Alternatively, several shared risk factors for AF, such as increasing age, diabetes mellitus, hypertension, and smoking, have been associated with endothelial dysfunction. [14] [15] [16] [17] [18] Potentially, these conditions increase the level of vascular endothelial dysfunction and predispose individuals to AF. However, our results remained significant after adjustment for these risk factors, suggesting that the association between endothelial dysfunction and AF is not completely explained by shared risk factors.
Brachial FMD has been shown to independently predict incident CVD events among people who are free of CVD at baseline. 5 Abnormal FMD values possibly identify individuals with subclinical atherosclerosis who are at-risk for CVD. In addition, as evidenced by our results, FMD potentially is able to identify persons who are at-risk for AF. However, further research is needed to examine the predictive ability of FMD for AF among at-risk populations before screening programs that use FMD are introduced.
Our results should be interpreted in the context of certain limitations. Paroxysmal cases of AF possibly were missed because of its time-dependent nature. Incident AF cases were ascertained from hospitalization discharge records and inpatient Medicare claims data using International Classification of Disease codes, which possibly resulted in misclassification. However, this method has been reported to have adequate positive predictive value for AF case identification. [19] [20] [21] Brachial FMD measurements were obtained during the initial MESA visit and the association of FMD with AF may vary with repeat FMD measurements. The clinical significance of the FMD values (eg, increase per 1-SD, median) used in this study is unknown and those used were designed to demonstrate exploratory associations (eg, lower FMD values are associated with increased AF risk). Future studies are needed to define clinically relevant values. Nonsignificant interactions were observed by age, sex, and race/ethnicity but the current analysis potentially was underpowered to detect such differences. Furthermore, our results are limited regarding generalizability to other populations because of the older age of participants with FMD values lower than the median value for study participants.
In conclusion, we have shown that brachial FMD values are inversely associated with incident AF in MESA. Our results suggest that endothelial dysfunction precedes the development of AF and may play an important role in the pathogenesis of this common arrhythmia. Further research is needed to confirm our findings and also to explore the clinical use of FMD to identify those who are at-risk for developing AF.
